{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-046804","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2026-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.045502+00:00","generated_at":"2026-05-15T04:50:25.974589+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Fennec announces four PEDMARK abstracts accepted at 2026 ASCO meeting","bullets":["Four abstracts evaluating PEDMARK accepted for presentation/publication at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago).","Key poster: STS-J01 study on delayed sodium thiosulfate for cisplatin-induced ototoxicity in pediatric/adolescent patients.","Other posters: randomized phase 1 trial in men with metastatic germ cell tumor; real-world feasibility in young adults; audiometric outcomes in head and neck cancer.","Full abstracts will be available on ASCO website May 21, 2026 at 5:00 p.m. ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-046804","json":"https://secwatch.observer/filing/0001104659-26-046804.json","markdown":"https://secwatch.observer/filing/0001104659-26-046804.md","text":"https://secwatch.observer/filing/0001104659-26-046804.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000110465926046804/0001104659-26-046804-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000110465926046804/fencf-20260422x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:50:25.974589+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}